PrKORSUVA®: Delivered 3 times a week, as an intravenous (IV) bolus at the end of HD1*
Recommended dose
0.5 mcg/kg dry body weight (i.e., the target postdialysis weight) by IV bolus injection
3X per week
The total dose volume (mL) required from the vial should be calculated as follows:
0.01 x target dry body weight (kg), rounded to the nearest tenth (0.1 mL).
† >1 vials may be necessary if an injection volume of >1 mL is required.
‡ The maximum target dry body weight of patients treated with difelikefalin evaluated in the placebo-controlled Phase 3 clinical trials was 135.0 kg. Population pharmacokinetic simulations demonstrated comparable difelikefalin exposure up to 200 kg.
Administration
Day 1
HD session 1
KORSUVA
injection
(0,5 mkg)
HD session 2
KORSUVA
injection
(0,5 mkg)
HD session 3
KORSUVA
injection
(0,5 mkg)
Day 7
Administer KORSUVA 3 times per week by IV bolus injection into the venous line of the dialysis circuit at the end of each HD session. It may be given either during or after rinse back of the dialysis circuit.
If the dose is given after rinse back, administer KORSUVA into the venous line followed by at least 10 mL of sodium chloride 9 mg/mL (0.9%) solution.
If the dose is given during rinse back, no additional sodium chloride 9 mg/mL (0.9%) solution is needed to flush the line.
The dose must be administered within 60 minutes of the completion of the syringe preparation.
Store at room temperature (15°C to 30°C). Do not freeze.
* Please see Product Monograph for complete dosing and administration information.